1. Use of fluoroquinolones and the risk of aortic and mitral regurgitation: A nationwide case-crossover study.
- Author
-
Chou AH, Lin CP, Chen CY, Wu VC, Cheng YT, Chan YH, Hsiao FC, Chen DY, Hung KC, Chu PH, and Chen SW
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Retrospective Studies, Taiwan epidemiology, Adult, Anti-Bacterial Agents adverse effects, Risk Factors, Fluoroquinolones adverse effects, Mitral Valve Insufficiency chemically induced, Mitral Valve Insufficiency epidemiology, Cross-Over Studies, Aortic Valve Insufficiency chemically induced, Aortic Valve Insufficiency epidemiology
- Abstract
Background: Recently, there have been conflicting results reporting an increased risk of AR or MR associated with oral fluoroquinolones (FQs).This study investigated whether the use of FQs increases the risk of mitral regurgitation (MR) or aortic regurgitation (AR)., Methods: A retrospective cohort study was conducted by using the Taiwan National Health Insurance research database. A unidirectional case-crossover design without selecting controls from an external population was adopted in this study. A total of 26,650 adult patients with new onset of AR or MR between January 1, 2000, and December 31, 2012, were identified. The risk of outcomes was compared between the hazard period and one of the randomly selected referent periods of the same individuals., Results: Before exclusion of pneumonia diagnosed within 2 months before the index date, patients who took FQs had a significantly greater risk of AR or MR (adjusted odds ratio [aOR] 1.51, 95% confidence interval [CI] 1.30-1.77), any AR (combined AR and MR) (aOR 1.50, 95% CI 1.10-2.04), and any MR (combined AR and MR) (aOR 1.37, 95% CI 1.16-1.62). After exclusion of pneumonia, FQs exposure remained significantly associated with a greater risk of MR (aOR 1.38, 95% CI 1.17-1.62) and any MR (aOR 1.25, 95% CI 1.05-1.48)., Conclusions: The findings suggested that patients treated with FQs could be warned about the potential risk for MR even after considering the possibility of protopathic bias. Reducing unnecessary FQs prescriptions may be considered to reduce the risk of valvular heart disease., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Chou et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF